Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | TP53 | P04637 | 3/20 | 0.68 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17731963 | 0.85 | NOTUM (0.63) | MAPTTP53NOTUMMAPK1ALDH1A1 | |
| SCHEMBL5621323 | 0.84 | MAPK1 (0.78) | MAPTTP53NOTUMMAPK1HDAC3 | |
| SCHEMBL28393948 | 0.81 | TP53 (1.00) | MAPTTP53NOTUMMAPK1ALDH1A1 | |
| SCHEMBL19814196 | 0.81 | MAPT (0.73) | MAPTTP53NOTUMMAPK1HDAC6 | |
| SCHEMBL3245809 | 0.80 | MAPT (0.67) | MAPTTP53NOTUMMAPK1HDAC3 | |
| SCHEMBL18091774 | 0.78 | TP53 (0.60) | MAPTTP53NOTUMMAPK1ALDH1A1 | |
| SCHEMBL5620616 | 0.78 | MAPT (0.72) | MAPTTP53NOTUMMAPK1ALDH1A1 | |
| SCHEMBL5621967 | 0.77 | NOTUM (0.67) | MAPTTP53NOTUMMAPK1ALDH1A1 | |
| SCHEMBL15498742 | 0.77 | TP53 (0.75) | MAPTTP53NOTUMMAPK1ALDH1A1 | |
| SCHEMBL18003867 | 0.76 | MAOA (0.51) | MAPTTP53HDAC3HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169797-B2 | Protein-tyrosine phosphatase inhibitors and uses thereof | ABBOTT LABORATORIES (US) | 2007-01-30 | — | — | US | disclosed |
| US-20040214870-A1 | Controlling gene expression; antidiabetic agents; insulin resistance; autoimmune disease; 5-(3-((1E)-3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid | ABBVIE INC. | 2004-10-28 | — | — | US | disclosed |
| US-20040167188-A1 | Controlling gene expression; antidiabetic agents; insulin resistance; autoimmune disease; | ABBOTT LABORATORIES | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167188-A1 | Controlling gene expression; antidiabetic agents; insulin resistance; autoimmune disease; | G6PC1, PPP1R1B, PPP1R7 | MAPT 4720/4885TP53 3557/4885NOTUM 2476/4885 |
| US-20040214870-A1 | Controlling gene expression; antidiabetic agents; insulin resistance; autoimmune disease; 5-(3-((1E)-3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid | G6PC1, PPP1R7, PPP1R1B | MAPT 4723/4885TP53 4168/4885NOTUM 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.